Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,231 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Rett Syndrome
Interventions: NNZ-2566, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas

Conditions: Non-Cystic Fibrosis Bronchiectasis
Interventions: Brensocatib 10 mg, Brensocatib 25 mg, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Peoria, Arizona • Newport Beach, California + 30 more

Conditions: Acute Heart Failure, Heart Failure
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: The TIMI Study Group; Other
Eligibility: 18 Years and older
Enrollment: 2,401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bullous Pemphigoid
Interventions: QGE031, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Iowa City, Iowa • Durham, North Carolina

Conditions: Sanfilippo Syndrome
Interventions: Recombinant human heparan N-sulfatase [rhHNS]; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Months to 48 Months
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Torrance, California • Minneapolis, Minnesota • Chapel Hill, North Carolina

Conditions: Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions: L606, Placebo; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 13
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: Osteoarthritis, Arthritis, Pain
Interventions: Placebo IV, Placebo SC, Tanezumab SC, Tanezumab IV; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 91
States / cities: Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more

Conditions: Alzheimer Disease
Interventions: Low Dose Benfotiamine, High Dose Benfotiamine, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 89 Years
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: ABT-089, atomoxetine, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 6 Years to 12 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Little Rock, Arkansas • El Centro, California • Boulder, Colorado + 17 more

Conditions: Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions: Dronabinol Capsules, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Hosuton, Texas • Houston, Texas

Conditions: Refractory Partial Seizures
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Office Hysteroscopy and Endometrial Biopsy
Interventions: Misoprostol 50 mcg pesssary, Placebos; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Sarcoidosis
Interventions: Placebo, Golimumab, Ustekinumab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more

Conditions: Asthma
Interventions: dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more

Conditions: Pain
Interventions: transcranial direct current stimulation (tDCS), Lidocaine cream, Capsaicin cream, Control cream; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 50 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Aging
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 70 Years to 95 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Post Prandial Distress Syndrome
Interventions: Placebo, 20 mg ATI 7505, 40 mg ATI 7505, 80 mg ATI 7505; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 44
States / cities: Chino, California • Fresno, California • Los Angeles, California + 37 more

Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: Avacopan, Placebo, Standard of Care; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 62
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more

Conditions: Alzheimer Disease
Interventions: ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo; Biological · Drug
Lead sponsor: Alzamend Neuro, Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Doral, Florida

Conditions: Hip Arthroplasty
Interventions: Extended Release Epidural Morphine (EREM), Placebo; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Multiple Sclerosis
Interventions: e-Support group, e-Journaling placebo; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: UX007, Placebo; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year to 100 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Aurora, Colorado • Miami, Florida • Orlando, Florida + 4 more

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Search by objective public record fields.

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Misoprostol in Office Hysteroscopy and Endometrial Biopsy

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

Neuromodulation of Lidocaine and Capsaicin Cream Effects on Pain Experience

Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly

A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing

E-Support Groups in Multiple Sclerosis

Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)